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Human immunodeficiency virus type 1 (HIV-1)-mediated depletion of CD4 lymphocytes in an infected
individual is the hallmark of progression to AIDS. However, the mechanism for this depletion remains unclear.
To identify mechanisms of HIV-1-mediated CD4 T-cell death, two similar viral isolates obtained from a rapid
progressor patient with significantly different pathogenic phenotypes were studied. One isolate (R3A) demon-
strates enhanced pathogenesis in both in vivo models and relevant ex vivo lymphoid organ model systems
compared to another isolate, R3B. The pathogenic determinants were previously mapped to the V5-gp41
envelope region, correlating functionally with enhanced fusion activity and elevated CXCR4 binding affinity. To
further elucidate specific differences between R3A and R3B within the V5-gp41 domains that enhance CD4
depletion, R3A-R3B chimeras to study the V5-gp41 region were developed. Our data demonstrate that six
residues in the ectodomain of R3A provide the major determinant for both enhanced Env-cell fusion and
pathogenicity. Furthermore, three amino acid differences in the heptad repeat 2 (HR-2) domain of R3A
determined its fusion activity and significantly elevated its pathogenic activity. The chimeric viruses with
enhanced fusion activity, but not elevated CXCR4 affinity, correlated with high pathogenicity in the thymus
organ. We conclude that the functional domain of a highly pathogenic HIV-1 Env is determined by mutations
in the HR-2 region that contribute to enhanced fusion and CD4 T-cell depletion.
Human immunodeficiency virus type 1 (HIV-1) is the caus-
ative agent for AIDS, which is characterized by a dramatic loss
of CD4 lymphocytes and impairment of the immune system
against invading pathogens (13, 21, 22). Though much has
been determined regarding interactions between HIV-1 virus
and CD4 target cells, the mechanisms by which the HIV-1
virus depletes CD4 lymphocytes remain incompletely under-
stood. Various studies have demonstrated that in an HIV-
infected host, both infected and uninfected cells are prone to
destruction, albeit by different pathways (15, 18, 29). Recently,
our group and others have shown that while binding of CD4
and chemokine receptors contribute to syncytium formation in
vitro, viral membrane fusion by the envelope glycoprotein
plays an important role in depletion of both uninfected and
infected cells by HIV-1 and simian-human immunodeficiency
virus in vivo (1, 11, 12, 26, 29).
HIV-1 entry into a cell is mediated by a multistep process
that begins with high-affinity binding between viral envelope
(gp120) and the cellular CD4 receptor (9, 14, 16). This binding
causes a conformational change in the viral envelope, allowing
for subsequent coreceptor binding (mainly CCR5 or CXCR4).
Upon coreceptor binding, another conformational change is
thought to take place that allows gp41 to engage the cell to
form a fusion complex. Envelope proteins have been demon-
strated to exist as a trimer, allowing for three gp41s to form a
fusion assembly through noncovalent interactions. This fusion
assembly is determined to exist in a six-helix bundle formation
as the fusion event takes place, allowing for the virion to fuse
to the host cell (5, 24).
The envelope glycoprotein (Env) of HIV plays a significant
role in viral pathogenesis, as seen in several in vitro and in vivo
models of infection. The Env functions to mediate virus entry
of cells and is also a major target for immune responses (31,
39). While the envelope initially forms as a precursor protein
(gp160), subsequent cleavage by a cellular protease yields the
surface subunit gp120 and the transmembrane gp41 although
the gp120 and gp41 interact noncovalently (36). The gp120
protein is comprised of five variable (V1 to V5) and five con-
served constant (C1 to C5) domains and binds CD4 and the
coreceptors. The gp41 protein is comprised of an amino-ter-
minal fusion domain and two heptad repeats (HR-1 and HR-2)
in the ectodomain (extracellular domain), a single transmem-
brane domain, and a cytoplasmic tail (intracellular domain) (8,
10, 36, 37). Due to the discovery of fusion inhibitor peptides
such as C34 (23, 24) and T20 (38), much is now known about
the fusion complex formed by the HIV-1 fusion domain. Sim-
ilar to other viral envelopes that carry a type 1 fusion complex
(such as influenza and corona viruses), the ectodomain of
HIV-1 Env carries two HRs that form a coiled-coiled structure.
In order for HIV-cell fusion to occur, the HR-1 domains of the
trimeric Env protein must interact with the cell surface. Fol-
lowing this initial interaction, HR-2 domains are thought to
intertwine over the HR-1 coils to form a stable six-helix bun-
dle, which represents the gp41 core structure. X-ray crystallo-
graphic studies show that the six-helix bundle core consists of
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the HR-1 and HR-2 peptides bound in an antiparallel manner.
This structure brings the fusion peptide to the target cell mem-
brane, allowing for the formation of a fusion pore and the
entry of virions into the cell.
HIV-1 Env expressed on the surface of infected cells can
induce cell-cell fusion with adjacent uninfected cells to form
multinucleated syncytia and single cell lysis in cell culture and
apoptosis in primary cells. Various models (both ex vivo and in
vivo) have been utilized to study HIV-1-induced depletion of
CD4 lymphocytes. Models such as SCID-human thymus-liver
(SCID-hu thy/liv), tonsil histoculture, and human fetal thymus
organ culture (HFTOC) have demonstrated significant use in
the study of acute infection and pathogenesis in the appropri-
ate lymphoid organ microenvironment as they retain the organ
structure and do not require exogenous stimulation for pro-
ductive viral infection to occur (2, 20, 28, 32). More impor-
tantly, tissue culture-adapted HIV-1 isolates such as HXB2 fail
to replicate in the SCID-hu thy/liv or HFTOC models (30, 33).
Organ models such as the SCID-hu thy/liv and HFTOC thus
more accurately demonstrate infection, replication, and patho-
genicity of primary HIV-1 strains.
Here, HFTOC is used to investigate mechanisms by which
an HIV-1 virus with a highly pathogenic viral Env is able to
deplete CD4 lymphocytes. Two viral isolates obtained from
rapid progressor patient 3 of the ALIVE cohort (40) show
significant sequence homology, particularly in the Env region,
while they carry stark differences in pathogenic ability (26, 27).
One isolate (denoted R3A) was found to demonstrate en-
hanced fusion in cell-cell fusion assays as well as enhanced
pathogenesis in relevant ex-vivo/in vivo organ model systems
compared to another isolate, R3B. To define the pathogenic
determinants that differentiate R3A from R3B, this study dem-
onstrates that the enhanced fusogenicity of R3A (governed by
the ectodomain of the gp41), but not the elevated CXCR4
binding affinity, confers the pathogenic phenotype in HFTOC.
We further demonstrate that three amino acid differences in
the HR-2 domain allow for this enhanced fusion for R3A
Env, defining a possible mechanism for a pathogenic HIV-1
envelope.
MATERIALS AND METHODS
Cells. A293T and Magi-CXCR4 cells (obtained from the NIH AIDS Research
and Reference Reagent Program) were cultured in Dulbecco’s modified Eagle
medium supplemented with 10% (vol/vol) bovine calf serum (Sigma Chemical,
St. Louis, MO) and 100 g/ml of penicillin and streptomycin. SupT1 and BC7
cells(catalog no. 100 and 11434, respectively; NIH AIDS Research and Refer-
ence Reagent Program, Division of AIDS, National Institute of Allergy and
Infectious Diseases [NIAID], NIH, from James Hoxie) were cultured in RPMI
1640 medium supplemented with 10% (vol/vol) bovine calf serum and 100 g/ml
penicillin and streptomycin. HOS-CXCR4 cells (HOS-CD4-Fusin; obtained
through the AIDS Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH, from Nathaniel Landau [3]) were stably transfected to express long
terminal repeat (LTR)-driven luciferase and were cultured in Dulbecco’s mod-
ified Eagle medium supplemented with 10% (vol/vol) bovine calf serum and 100
g/ml penicillin and streptomycin. All virus isolates were prepared and stored in
Iscove’s modified Dulbecco’s medium supplemented with 10% (vol/vol) bovine
calf serum and 100 g/ml penicillin and streptomycin. Peripheral blood mono-
nuclear cells (PBMCs) were purified from the blood of healthy HIV-1-negative
donors by Ficoll-plaque density gradient centrifugation and cultured in Iscoves
modified Dulbecco’s medium supplemented with 10% bovine calf serum and 100
g/ml penicillin and streptomycin. PBMCs were stimulated with 5 g/ml of
phytohemagglutinin (Sigma) and 20 units/ml recombinant interleukin-2 (Sigma)
for 3 days and then cultured in 20 units/ml recombinant interleukin-2.
Virus isolates and drugs. Isolation of Env from primary isolates and cloning of
NL4-R3A and NL4-R3B have been previously described (27). Peptide C34 was
synthesized by at the MicroChemistry Laboratory of the New York Blood Center
(kindly provided by S. Jiang). C34 was reconstituted in phosphate-buffered saline
at a concentration of 1 mg/ml.
Chimeric envelope construction. R3A and R3B envelope chimeras were de-
veloped in a retroviral vector (high-titer, stem cell, pGK-GFP [HSPG]) (6, 27)
using an overlap PCR strategy with the following primers: V3F, GTAACTCTA
GGACCAGGCAGAG; V5F, GCTGTGTTCCTTGGGTTCTTGG; V5R, CCA
AGAACCCAAGGAACACAGC; gp41F, CACCATTATCGTTCCAGACCCG;
gp41R, CGGGTCTGGAACGATAATGGTG, and HSPGR, CTAAAGCGCA
TGCTCCAGACTG. Chimeric Env regions were cloned back into the HSPG
vector expressing Env and verified by both restriction digestion and sequence
analysis. A half-virus strategy was utilized to clone the chimeric Env proteins into
the full-length NL4.3 backbone, and progeny virus was developed by transfection
into A293T cells. Site-directed mutagenesis was performed to create single
amino acid changes in the ectodomain of R3A, and these were verified by
sequence analysis.
Virus production. Vesicular stomatitis virus G protein pseudotyped retrovirus
was produced by calcium phosphate cotransfection of A293T cells with vesicular
stomatitis virus G protein, Gag/Pol, and HSPG retroviral DNA as previously
described (4, 27). The HSPG retroviral construct contains green fluorescent
protein under the control of the phospho-glucose kinase promoter (after trans-
fection) or the murine stem cell virus LTR (after transduction). Viral superna-
tant was harvested at 48 and 72 h posttransfection, clarified by low-speed cen-
trifugation, aliquoted, and frozen at 70, as previously mentioned. Infectious
virus for R3A and R3B chimeras was derived as follows: chimeric Env proteins
were cloned into p83.10 plasmid containing a partial NL4 genome (EcoRI to
XhoI) and cotransfected into A293T cells with the p83.2 plasmid containing the
remaining NL4.3 genome. Supernatant was harvested at 48 h posttransfection
and cocultured with stimulated PBMCs. Pseudotyped NL4-luciferase viruses
(pNL4-3.Luc.R-E; obtained through the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH, from Nathaniel Landau) (7,
17) expressing chimeric Env proteins were generated by cotransfection of pNL4-
Luc and HSPG Env proteins into A293T cells as mentioned previously. Viral
supernatants were harvested daily and were tittered for expression of Gag by p24
enzyme-linked immunosorbent assay (ELISA).
Virus quantitation. Gag was detected in virus stocks as well as supernatant
from HFTOC infections using a p24 ELISA kit (AIDS Vaccine Program, NIH).
Viruses were quantified for the number of infectious units/ml by infection of
Magi (CXCR4) cells, as we have reported previously (27, 30, 33).
HFTOC. The procedure for infection and culture of human fetal thymus has
been previously described (26–28). In brief, human fetal thymuses (19 to 22
weeks of gestation) were dissected into 2-mm2 fragments, using a dissecting
microscope to retain the lobe structure for each fragment.
Four fragments placed on organotypic culture membranes (Millipore) and
underlaid with HFTOC medium (previously described) were plated in six-well
tissue culture plates. Thymic fragments were infected with equivalent amounts of
virus (100 to 800 IU) in 15 l per fragment. Viral and mock supernatants were
derived from the same donor sample per experiment.
Thymic fragments were cultured at 37°C in 5% CO2 for the length of each
experiment. On the experiment harvest day, thymic fragments were disassociated
in 350 l of phosphate-buffered saline with 2% fetal bovine serum using pestles
(Bellco Co.) for fluorescence-activated cell sorting (FACS) analysis.
FACS analysis. Thymocytes (and other cells) were stained with CD4-phyco-
erythrin and CD8-fluorescein isothiocyanate antibodies (Caltag) for surface
staining. Cell viability was assessed using staining for 7-aminoactinomycin D.
Analysis was performed using Summit software, as previously reported.
Virus-cell fusion analysis. NL4-luciferase pseudotyped virus expressing R3A,
R3B, and chimeric Envs was generated by transfection of 293T cells. Viruses
were titered by Magi assay, and SupT1 cells were infected by spinoculation and
then cultured for 48 h. At endpoint, cells were harvested and lysed for luciferase
analysis. Luciferase was measured using luciferase assay buffer reagents (Pro-
mega) and a Fluorstar luminometer.
Cell fusion analysis. BC7 cells were transduced with retrovirus to express HIV
Env, which was assessed for relative expression by FACS analysis by staining with
2G12 (HIV-1 gp120 monoclonal antibody at 10 g/ml; obtained through the NIH
AIDS Research and Reference Reagent Program, Division of AIDS, NIAID,
NIH, from Hermann Katinger). Cells were then cocultured with HOS/LTR-
luciferase cells for 48 h, at which time cells were pelleted and lysed for luciferase
activity. To measure the rate of fusion of various Env-expressing BC7 cells to
HOS/LTR-luciferase cells, C34 was added to wells (10 g/ml) to inhibit fusion at
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various time points, and cells were then pelleted and lysed at 48 h for luciferase
activity.
Statistical analysis. Both a Student’s t test and nonparametric Mann-Whitney
tests were performed to determine statistical significance of data. All analysis was
performed using GraphPad Prism software.
RESULTS
The enhanced pathogenicity of R3A envelope is determined
by mutations in the gp41 ectodomain. We have previously
demonstrated that the R3A Env is significantly more patho-
genic than R3B Env in the thymus organ models. The en-
hanced pathogenicity of R3A Env is correlated with high
CXCR4 binding and more fusogenic activity than R3B (26–
28). Specifically, chimeric viruses containing the V5 and gp41
domains of R3A in the R3B envelope background demon-
strated an elevated pathogenic phenotype of CD4 lympho-
cyte depletion compared to the parental NL4-R3B virus. Five
differences exist in the V5 domains of the R3A and R3B
envelope while 10 amino acid differences exist in the gp41
regions, with six differences in the ectodomain and four differ-
ences in the cytoplasmic tail of the R3A Env. In order to
determine which amino acid differences in these domains of
the R3A envelope contribute to pathogenesis, chimeric R3A
and R3B Envs were created (Fig. 1A). One chimera (denoted
R3A/B-gp41) carried the entire gp120 of R3A with the R3B
gp41. The second chimera (R3A/B-cytoplasmic tail) retained
the R3A gp120 and the ectodomain of gp41, while carrying the
gp41 cytoplasmic tail of R3B. The third chimera (R3B/A-
ectodomain) carried the R3A ectodomain in the R3B Env.
Upon transfection of Env-expressing plasmids into A293T
cells, Western blot analysis was performed to show that all
HIV-1 recombinant Env proteins were similarly expressed and
processed (data not shown). To further show surface expres-
sion of HIV Envs, surface expression on A293T cells was
assessed using FACS analysis. Similar surface levels of all re-
combinant Env genes were detected by staining with the 2G12
antibody (Fig. 1B), which binds the glycolsylated gp120 (34).
To determine whether specific regions of R3A play a role in
CD4 cell depletion, recombinant HIV-1 with the R3A/R3B
chimeric Envs in the NL4.3 backbone were produced and stud-
ied. Recombinant viruses have similar replication and CD4
depletion characteristics in phytohemagglutinin-activated pe-
ripheral blood lymphocytes in vitro. Infection of activated
PBMCs demonstrated that the viruses were equivalently infec-
tious, as assessed by p24 Gag protein (data not shown). We
found that there was no difference in virus production levels
between the recombinant viruses, as we have previously re-
ported with R3A and R3B in activated PBMCs (28). CD4
lymphocyte depletion was assessed by FACS analysis over sev-
eral time points, and depletion was also found to be equivalent
by parental strains and chimeras over time (Fig. 1C).
In human lymphoid organs R3A shows elevated pathogenic
activity, which has been mapped in the gp120 V5 and the gp41
regions (28). In order to further dissect the determinants
within the V5-gp41 region that impact CD4 cell depletion by
R3A Env, the R3A/R3B chimeric viruses were used to infect
human fetal thymus fragments (HFTOC). At various time
points after infection, the viral p24 level in the HFTOC super-
natant was measured using an ELISA for p24 antigen. Virus
replication over 11 days of HFTOC infection was found to be
different (Fig. 2A) in that NL4-R3A and viruses possessing the
R3A gp41 ectodomain replicated to higher levels than NL4-
R3B and viruses carrying the R3B gp41 ectodomain (R3A/B-
gp41). On day 11 postinfection, fragments were harvested, and
thymocyte cells were counted and analyzed by FACS analysis.
Upon infection of HFTOC, a significant difference in CD4
thymocyte depletion levels between R3A and R3B was de-
tected (Fig. 2B). Thus, NL4-R3A depleted CD4 lymphocytes
by 80% while NL4-R3B depleted cells by only 40%. The rel-
ative depletion of CD4 thymocytes by NL4-R3A/B-gp41 was
significantly lower than that by NL4-R3A but not different
from NL4-R3B. Both the chimera NL4-R3A/B-cytoplasmic tail
and R3B/A-ectodomain depleted CD4 cells to levels similar
depletion by NL4-R3A, and both were significantly more
pathogenic than NL4-R3B. Therefore, enhanced replication
and CD4 thymocyte depletion of R3A in the HFTOC model
were determined by the six amino acid differences between
R3A and R3B in the ectodomain of gp41.
The HR-2 of R3A gp41 determines the enhanced fusion
ability of R3A. The ectodomain of HIV-1 gp41 encodes the
fusion domain and two HRs, thereby allowing the virus to
enter the host cell (5, 24, 25). It has been previously demon-
strated that R3A Env confers enhanced fusion ability to cells
compared to R3B Env (26, 27). The R3A and R3B Env genes
encode the same fusion peptide in gp41. Thus, other determi-
nants in the ectodomain of R3A Env must be important. The
ectodomain also contains the N-terminal HR(HR-1), a miniloop
region, and the C-terminal HR (HR-2). From sequence anal-
ysis (using HXB2 for consensus) (28), two amino acid changes
(Q543R and Q564H) exist in HR-1, three exist in HR-2
(S644N, N651I, and E665K), and one occurs in the cysteine
miniloop region between the two HR domains (H620D). It is
possible that changes in an ectodomain could alter the inter-
action either between the HR-1 domain with the HR-2 domain
or between the HR-1 domains in the coil-coil formation, lead-
ing to either enhanced or reduced fusion. A modeling diagram
was constructed over the known crystal structure for the
ectodomain of HIV-1 gp41 (5) carrying the individual amino
acid differences between the R3A and R3B Envs (Fig. 3A).
The crystal structure for the thermodynamically stable HIV-1
viral fusion protein contains 36 amino acids of HR-1 and 34
amino acids of HR-2 (25). Only three of the R3A/R3B differences
exist within the known structure. As reported, C34 helices pack
outside the N36 helices in an antiparallel fashion, and our map-
ping suggests that the changes that map to the N- and C-terminal
HRs are unlikely to contribute to a direct HR-1–HR-2 interaction
that could lead to an altered fusion phenotype. However, one
upstream difference in HR-1 (Q543R), as well as one down-
stream difference in HR-2 (E665K), could not be mapped on the
known structure. Further, the difference that maps to the cysteine
miniloop region between the HRs also cannot be mapped
(H620D) as this region does not exist within the crystal structure.
Despite the mentioned limitations presented by the model, amino
acid changes were inferred to exist on the outer regions of the
helices, suggesting that an interaction due to mutation was not
likely. Rather, individual changes may have conferred the ob-
served fusion ability.
Site-directed mutagenesis of each amino acid site in the
R3A HR-1/HR-2 region was performed to determine if sub-
stituting individual R3B changes in the R3A background
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would impact the Env’s ability to fuse (Fig. 3B). A cell-cell
fusion assay was utilized to determine whether single changes
in the R3A extracellular domain would affect the high-fuso-
genic phenotype. Retroviral vectors that express the various
HIV-1 Envs and Tat were used to transduce BC7 cells. Upon
coculture with HOS/LTR-luciferase cells expressing the nec-
essary receptors CD4 and CXCR4, fusion from Env-cell fusion
was quantified by luciferase activity due to Tat activation of
LTR-luciferase. Our results show that R3A Env promoted
levels of fusion on average fivefold higher than R3B Env, and
Envs with single point mutations had similar levels of fusion to
the parental R3A Env. We concluded that individual amino
acid changes in the ectodomain did not affect the fusion ability
of R3A Env (Fig. 4A).
We have previously reported that both R3A and R3B Envs
were equivalently sensitive to fusion inhibitor T20 (26) or C34
(data not shown). As T20 or C34 is derived from the HR-2
sequence and binds to the HIV-1 Env HR-1 to inhibit fusion,
we thus first focused on whether changes in the R3A HR-2
domain could alter fusion ability. To test the hypothesis that
the R3A HR-2 domain contributes to enhanced fusion activity,
chimeras were produced by exchanging the HR-2 domains
between R3A and R3B (Fig. 3B). Interestingly, the R3A chi-
mera containing the R3B HR-2 significantly reduced fusion
ability while the R3B chimera containing the R3A HR-2 dem-
onstrated a higher fusion function (Fig. 4B).
To determine whether the exchange of HR-2 domains would
affect virion-mediated fusion or virus entry into host cells,
pseudotyped viruses with HIV-1 Envs and NL4-luciferase were
generated and used to transduce SupT1 cells (Fig. 4C). The
data show that the increased entry of R3A is significantly
attributed to the HR-2 domain as viruses carrying the R3A
HR-2 domain demonstrate enhanced ability to enter host cells
FIG. 1. R3A, R3B, and chimeric recombinants. (A) A schematic diagram of R3A and R3B Envs and their gp41 chimeric recombinants. Six
amino acid differences exist between R3A and R3B within the ectodomain (Ecto), and four exist within the cytoplasmic tail (Cyto T) domain.
(B) Cell surface expression of Env proteins is equivalent between R3A, R3B, and the chimeric Env. Staining with 2G12 monoclonal antibody was
performed for FACS analysis of 293T cells transfected with Env-expressing vectors. Relative expression levels are presented as mean fluorescence
intensity (MFI). (C) R3A, R3B, and their HIV-1 recombinants show similar infection and CD4 T-cell depletion levels in activated PBMCs.
Activated PBMCs were infected with HIV-1 stocks with parental or chimeric R3 Env genes. Relative CD4 T-cell depletion (with mock samples
as 100%) is shown at 6, 9, and 12 days postinfection. Error bars represent standard deviations from triplicate samples. d, day; PE, phycoerythrin.
FIG. 2. The R3A ectodomain determines its higher pathogenic activity in vivo. HIV-1 viruses encoding the R3A, R3B, or the chimeric Env
genes were used to infect HFTOC. (A) HIV-1 replication was measured from supernatants harvested from HFTOC at 7, 9, and 11 days
postinfection. Shown are combined data at days 7 to 9 postinfection. (B) Relative HIV-1 pathogenesis (depletion of total CD4 thymocytes) in
HFTOC was assessed by FACS analysis, with the mock (M) sample set at 100%. Data demonstrate combined results from six independent
experiments. Error bars represent standard deviations. , P  0.05 relative to mock; , P  0.01 relative to R3B. Cyto T, cytoplasmic tail; Ecto,
ectodomain.
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while viruses expressing R3B HR-2 demonstrate low entry
ability.
It is possible that changes in HR-2 provide an enhanced rate
of fusion for the R3A Env and, hence, more efficient entry. To
determine this possibility, a time course to measure the rate of
fusion of HIV-1 Envs was performed. BC7 cells expressing
HIV-1 Envs were first assessed for equal HIV-1 Env surface
expression by FACS analysis with the 2G12 anti-Env monoclo-
FIG. 3. Ectodomain recombinants of R3A and R3B. (A) A ribbon diagram depicts the changes seen between R3A and R3B in the ectodomain. Only
three of the six differences between R3A and R3B can be modeled upon the known crystal structure. These changes do not seem to change direct
interactions between the HR-1 and HR-2 domains. (B) The HR-2 domains were swapped between R3A and R3B Env genes. Individual amino acids in
the R3A Env gene were also changed to R3B residues using site-directed mutagenesis. Ecto, ectodomain; Cyto T, cytoplasmic tail; TM, transmembrane.
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nal antibody (Fig. 5A). Western blot analysis was also per-
formed to show that all HIV-1 recombinant Env proteins were
similarly expressed and processed in transfected cells (data not
shown). Equivalent numbers of Env/Tat-expressing cells were
cocultured with HOS/LTR-luciferase reporter cells on ice and
then placed at 37°C. Fusion inhibitor C34 was added at 0, 6,
and 12 h to inhibit fusion. After 48 h, cells were lysed, and
luciferase was measured to assess fusion. BC7 cells expressing
R3A Env demonstrated an enhanced fusion activity constitu-
tively over time compared to R3B-expressing cells, and this
enhanced fusion ability was correlated with the HR-2 domain
of R3A (Fig. 5B and data not shown). However, relative inhi-
bition of fusion of Envs encoding the R3A HR-2 was more
dependent on the early addition of C34 than the R3B Env.
Thus, C34 added at 6 h postinitiation of fusion inhibited only
70% of fusion mediated by R3A or R3B/A-HR-2 but still
completely inhibited R3B-mediated fusion. When added at
12 h postfusion initiation, C34 inhibited 40 to 50% of fusion by
R3A or R3B/A-HR-2 but still inhibited 80% of R3B-mediated
fusion. The data suggest that the R3A Env, through its unique
HR-2 domain, fuses with target cells more rapidly.
Our previous studies suggest that the enhanced CXCR4
binding affinity could be a determinant for pathogenicity of
R3A (26). As the R3A HR-2 was determined to be the major
contributor for fusogenicity, the domain’s role in CXCR4 bind-
ing affinity was analyzed. Analysis of CXCR4 binding affinity
was performed, and the R3B/A-ectodomain recombinant
showed intermediate resistance to the coreceptor antagonist
AMD3100 compared to resistance shown by R3A and R3B
(Fig. 6). Further, R3A/B-HR-2 and R3B/A-HR-2 showed
CXCR4 affinity similar to that of their parent viruses R3A and
R3B, respectively. As it has been shown that swapping of the
HR-2 domain also exchanges fusion activity of Env, there is
no clear correlation between CXCR4 binding affinity and en-
hanced fusogenicity.
The HR-2 domain of the R3A gp41 plays a significant role in
the enhanced pathogenic ability of R3A in the HFTOC model.
To address whether the R3A HR-2 also contributes to elevated
CD4 cell depletion in lymphoid organs, full-length HIV-1
viruses were generated that expressed chimeric HR-2 Envs to
compare against NL4-R3A and NL4-R3B. As previously re-
ported with R3A and R3B in activated PBMCs (26), similar
replication and CD4 depletion activities were observed with all
HIV-1 recombinants in activated PBMCs (data not shown).
HFTOC was infected with parent and chimeric viruses, and
both virus replication and CD4 cell depletion were assessed.
Enhanced virus replication was seen by NL4-R3A over NL4-
R3B, as observed previously (26). Interestingly, both R3A/B-
HR-2 and R3B/A-HR-2 chimeric viruses showed higher levels
of replication than R3B (Fig. 7A). Consistent with the fusion
activity, chimeric viruses with the R3A HR-2 domain were
found to deplete CD4 thymocytes more efficiently than viruses
with the R3B HR-2 domain (Fig. 7B). By Day 11 postinfection,
NL4-R3A was found to deplete CD4 cells by 90%, while
NL4-R3B or NL4-R3A/B-HR-2 depleted cells by only 30 to
40%. Interestingly, NL4-R3B/A-HR-2 showed an intermediate
level of CD4 cell depletion and was significantly more patho-
genic than NL4-R3B but less pathogenic than NL4-R3A.
These findings suggest that the R3A HR-2 contributes to the
enhanced CD4 cell depletion by R3A in the thymus organ,
but additional determinants in the R3A ectodomain also play
a role in enhanced pathogenesis. The entire ectodomain may
function in concert to enhance HIV infection and pathogene-
































































































FIG. 4. The HR-2 domain of R3A determines its enhanced fusion
activity. BC7 cells expressing various HIV-1 Tat and Env genes were
cocultured with cells expressing CD4, CXCR4, and LTR-luciferase.
Relative fusion is measured by the activation of HIV-LTR-luciferase
(measured by relative light units [RLU]) by Tat in the fused cells.
(A) Individual amino acid changes in the R3A Env gene do not
significantly affect the fusion phenotype of R3A. Site-directed muta-
tions of the R3A ectodomain carrying R3B changes were assayed, and
individual changes were not seen to confer an R3B-like phenotype.
(B) Swapping of the HR-2 domain completely exchanged the fusion
phenotype in the cell-cell fusion assay. (C) Swapping of the HR-2
domain also exchanges the HIV-1 virus-cell fusion phenotype. NL4-
luciferase pseudotyped with various R3 Env proteins was used to infect
SupT1 cells. Luciferase expression (RLU) was measured at 48 h
postinfection. Error bars represent samples in triplicates.
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the fusion activity, but not the CXCR4 affinity, is correlated
with the enhanced pathogenicity of R3A in lymphoid organs.
DISCUSSION
The virologic mechanisms by which human lymphoid organs
undergo CD4 cell depletion during HIV-1 infection remain
incompletely characterized. We have previously reported that
HIV-1-induced fusion is the major contributor to pathogenesis
of both infected and uninfected cells in human lymphoid or-
gans (26–28). In this report, we have investigated the virologic
determinants that contribute to the elevated fusogenicity and
pathogenicity of the R3A envelope. We discovered that the
gp41 ectodomain of R3A Env determines its high levels of
pathogenic and fusion activity. As this domain carries six
amino acid differences between the R3A and R3B Env, we
further determined that the three mutations in the HR-2 do-
main of R3A Env play a major role in its elevated fusion
activity and partially contribute to the high pathogenic activity
in the thymus organ model.
As a result of comparing Env chimeras of a highly patho-
genic virus with a less pathogenic virus, six amino acid dif-
ferences within the ectodomain were mapped to confer the
enhanced fusion and pathogenic ability of R3A. Individual
site-directed mutants did not impact the enhanced fusion
phenotype of R3A Env (Fig. 4). Thus, a functional deter-
minant consisting of redundant or complementary residues
in the R3A ectodomain or HR-2 is implicated in contribut-
ing to the enhanced fusogenic activity.
R3A and R3B Envs were similarly sensitive to fusion inhi-
bition by T20 or C34 (26). As T20 or C34 is an HR-2 homolog
which functions to bind to HR-1 and inhibit fusion, the
changes in the R3A HR-1 region were probably not involved in
the elevated fusion activity. Consistent with the prediction, the
three amino acid differences in the HR-2 domain of R3A were
necessary and sufficient to confer the enhanced fusion ability of
R3A Env. Three functional domains have been reported within
the HR-2 of the gp41 ectodomain: an HR-1 binding domain
(residues 628 to 666), a pocket binding domain (628 to 635),
and a lipid binding domain (666 to 673) (19). Interestingly, all
three differences in the HR-2s of R3A and R3B Envs are
FIG. 5. The R3A HR-2 domain confers accelerated fusion activity. (A) Equivalent expression of R3A, R3B, and their HR-2 chimeric
recombinant Env proteins on the surface of transduced BC7 cells. Surface expression of HIV Env on transduced BC7 cells was assessed by 2G12
staining and FACS analysis. Relative Env expression levels are presented as mean fluorescence intensity. (B) Recombinant Env genes encoding
the R3A HR-2 demonstrated accelerated fusion. Cells expressing various HIV Env genes were mixed with the fusion reporter cell line. Fusion
inhibitor C34 was added at the indicated time after coculture at 37°C. Inhibition of fusion of each recombinant Env by C34 when added at time
point 0 is calculated as 100% inhibition. Relative inhibition by C34 added at 6 and 12 h is shown. Data are representative of two independent
experiments, and error bars represent standard deviations derived from duplicate samples.
FIG. 6. The enhanced CXCR4 binding affinity of R3A Env is not
correlated with enhanced fusion activity. Resistance of each HIV-1
Env gene to the antagonist AMD3100 (200 nM) relative to R3A was
determined. Error bars represent standard deviations derived from
triplicate samples. , P  0.05; , P  0.01.
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encoded within the HR-1 binding domain. The HR-1 binding
domain of R3A Env is thus a major determinant of enhanced
fusion activity.
In addition to the elevated fusion activity associated with the
R3A Env, HIV-1 recombinants containing the R3A ectodo-
main depleted thymocytes equivalently to parental NL4-R3A,
suggesting that enhanced fusion may contribute significantly to
pathogenesis. Because increased CXCR4 binding efficiency
was previously suggested also as a determinant for thymic
pathogenicity (26), the R3B/A-ectodomain Env was assayed
for relative CXCR4 binding efficiency (Fig. 6). As was seen
with other chimeric Envs (expressed in pseudotyped virus)
(26), an intermediate level of CXCR4 binding efficiency was
observed. This intermediate phenotype was shared with chi-
meric Envs that demonstrated significantly less thymic patho-
genicity, suggesting that coreceptor binding efficiency and sen-
sitivity to coreceptor antagonist AMD3100 do not directly
correlate with the observed pathogenesis of the Env.
It is thought that the HR-2 domain functions to “zip” over
the HR-1 domain after the initial step of Env-cell fusion, so
the amino acid changes seen in the R3A HR-2 may allow a
more rapid ability to fuse the envelope to the cell, providing
for significantly enhanced ability for the Env to enter the
cell as well. It is possible that changes present in NL4-R3A
provide for an enhanced rate of fusion of the Env, which
allows for enhanced pathogenesis compared to NL4-R3B.
To provide various snapshots of fusion over time, fusion
inhibitor C34 was used to inhibit fusion at various time
points. Envs expressing R3A HR-2 showed enhanced and
accelerated fusion compared to Envs expressing R3B HR-2.
Envs expressing the R3A HR-2 provided more robust fusion
ability, with a significant difference in the slope of kinetics of
the R3A and R3B Envs.
We demonstrate that HR-2 is an important contributor for
both fusion and pathogenic activity in a relevant human lym-
phoid organ model. All three of the mutations in the R3A
HR-2 region lead to changes in hydrophobicity and charge.
Specifically, the R3A HR-2 carries changes to serine, aspara-
gine, and glutamic acid, which are all hydrophilic. The hydro-
philic nature of this region may shed light on the highly fuso-
genic ability of the R3A HR-2. Also, relative to the sequence
of R3B, in R3A the H to D at position 620 removes a partially
positive charge and replaces it with a negative charge, and E to
K at position 665 removes a negative charge and replaces it
with a positive charge. The HR-2 differences provide various
changes that may affect the conformation of the six-helix bun-
dle such that R3A HR-2 may interact differently with the viral
membrane than R3B HR-2. We analyzed HIV-1 sequences in
the Los Alamos National Laboratory HIV Sequence Database
for their sequence comparison with R3A and R3B. Of approx-
imately 500 clade B Envs, the Asp-651 in R3A Env is the
consensus whereas the Ile-651 in R3B is not reported in other
subtype B HIV-1 sequences. Interestingly, the Lys-665 in R3B
is the consensus, but Glu-665 of R3A is not detected in the
other subtype B HIV-1 strains. Amino acid 665 is the first
position of the membrane-proximal external region, which is
known to be a relatively conserved region that plays a distinct
role in fusion and is a target for antiviral drugs (35). It is
possible that this R3A mutation, in combination with other
mutations in the HR-2 region, may contribute to an enhanced
fusogenic phenotype.
Several groups have reported that HIV-1 Env-mediated
fusion is the primary determining factor in CD4 T-cell loss
(4, 11, 12). An enhancement of the ability of the Env to fuse
would lead to an increase in the efficiency of new infections
at the cost of higher amounts of cell death. Indeed, we have
reported the enhanced pathogenicity of a highly fusogenic
virus in the fetal thymus organ model. Further, we demon-
strate that enhanced fusion by R3A is directly due to the
HR-2 domain. The data from these experiments suggest that
FIG. 7. The R3A HR-2 domain contributes significantly to its en-
hanced pathogenesis in human lymphoid organs. R3A, R3B, and the
chimeric recombinants were used to infect HFTOC. (A) Viral repli-
cation was measured by p24 ELISA at 7, 9, and 11 days postinfection.
Shown are data from days 7 to 9 postinfection. (B) CD4 thymocyte
depletion was measured by FACS analysis at 11 days postinfection of
HFTOC with NL4-R3A, R3B, and chimeras. Error bars represent
standard deviations from samples in triplicate, and two independent
experiments were performed with similar results. , P  0.05 in com-
parison to R3B; , P  0.001 versus R3B.
VOL. 83, 2009 HIV-1 Env HR-2 DOMAIN IN FUSION AND PATHOGENICITY 11723
the entire structural change is necessary for R3A’s HR-2-
mediated effect. Interestingly, pathogenesis conferred by the
R3A ectodomain is not strictly due to the changes seen in
the HR-2, so other changes observed in the ectodomain
including HR-1 may contribute to the overall pathogenesis
of R3A. Future experiments will be performed to determine
interactions that may exist between the HR-1 and HR-2
domains that may provide this enhanced fusion-mediated
pathogenesis observed with the R3A ectodomain.
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